CJC-1295 Effect on CMP (Comprehensive Metabolic Panel): What Labs Actually Change

HealthRX.com

No CMP change is established for CJC-1295

1.5- to 3-foldMean IGF-I rise after one subcutaneous dose of the DAC formSource: pubmed.ncbi.nlm.nih.gov

Print or save as PDF

Key numbers

  • 45%Mean IGF-I above baseline one week after a single 60 or 90 microgram/kg dose in healthy menSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 5.8 to 8.1 daysEstimated half-life after one subcutaneous dose of the DAC form in healthy adultsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1.5- to 3-foldMean IGF-I rise after one subcutaneous dose of the DAC formSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • Approval / Not FDA-approved; three human studies, all in healthy volunteers [1]
  • CMP results / No CMP change established
  • Glucose / FDA ties GH and IGF-I elevation to glucose intolerance and diabetes [1]
  • Fluid retention / Named in the same FDA risk statement [1]
  • IGF-I rise / 1.5- to 3-fold for 9 to 11 days after one dose of the DAC form [2]
  • Half-life / 5.8 to 8.1 days after one subcutaneous dose of the DAC form [2]
  • Common events / Study 1: injection-site reactions about 70%; headache 63% vs 14% on placebo [1]

What is known about CJC-1295 and a CMP?

The results available for CJC-1295 cover growth hormone, IGF-I, pharmacokinetics and clinical adverse events. They do not establish any change in glucose, electrolytes, liver enzymes or kidney markers [1][2].

CJC-1295 is an investigational long-acting analogue of growth hormone-releasing hormone, and no form of it is FDA-approved [1]. It acts on the pituitary like GHRH to raise the body's own GH and, through GH, IGF-I [2][3]. FDA identified three published human studies, all of the DAC form and all in healthy volunteers, and described them as short, small and mostly single-dose, with long-term safety unknown [1].

What people on Reddit report

Self-reported lab results from people who combined a growth hormone peptide blend with other peptides and tracked hormone levels. These accounts cover testosterone and insulin-like growth factor, not a full CMP.

OIF_USMC0351 · Peptidesource

I did both. My testosterone went up from 610 to 670. My IGF-1 went from 227 to 273.

Reports that testosterone and insulin-like growth factor rose on bloodwork after using both peptides, alongside heavy gym training.

Read the source discussion

OIF_USMC0351 · Peptidesource

I used both to bulk up while not becoming fat. My labs show an increase in testosterone and IGF-1. Do with that as you will.

Reports rising testosterone and insulin-like growth factor on labs after combining the two peptides, and says the result may not suit everyone.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Glucose: the analyte with a stated reason to watch

FDA's concern about peptides that raise growth hormone is specific: GH and IGF-I elevation carries the risks listed on approved growth hormone labels, including glucose intolerance and diabetes, fluid retention, and tumor growth concerns [1]. That is a risk statement about the growth hormone axis, not a glucose measurement taken in people using CJC-1295.

IGF-I is the analyte the trials did measure. After one subcutaneous dose of the DAC form, mean IGF-I rose 1.5- to 3-fold and stayed above baseline for 9 to 11 days [2]. One week after a single 60 or 90 microgram/kg dose in healthy men, mean IGF-I was 45% above baseline, with no significant difference between the two doses [3].

Fluid retention and the events actually recorded

The same FDA statement names fluid retention [1]. The adverse events recorded in the trials were different. In the first Teichman trial, flushing, warmth and transient low blood pressure occurred in about 30% of treated subjects, injection-site reactions in about 70%, and headache in 63% versus 14% on placebo. Transient diarrhea also occurred, and two subjects had transient dizziness and low blood pressure. Most events were more common at 125 or 250 micrograms/kg, and no serious adverse reactions were reported in the two trials [1][2]. In the Ionescu study, heart rate rose with dose [1].

Liver and kidney markers

The safety concerns FDA posts for CJC-1295 are possible immunogenicity for certain routes, impurity and characterization problems, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data. Liver injury and kidney injury are not among them [4].

Regulatory status

FDA notes that CJC-1295 sold online is mostly labeled research use only, including blends with ipamorelin and GHRPs, and that research-use-only products are not FDA-approved drugs [1]. CJC-1295 was in category 2 (significant safety risks) but now sits in FDA's nominated-but-withdrawn table because the nominators withdrew; FDA's concerns remain posted [4]. It appears on neither FDA's list for state-licensed pharmacies and physicians nor its list for outsourcing facilities, so the category 1 policy does not apply to it [5][6]. FDA's advisory committee voted against adding each form: 0 yes and 13 no on the free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each of the three DAC forms [7].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. For how long did mean IGF-I stay above baseline after one dose of the DAC form?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Does CJC-1295 change CMP values?
No CMP change is established. The published human studies are described as tracking growth hormone, IGF-I, pharmacokinetics and adverse events [1][2]. FDA's stated concern for growth hormone-raising peptides is the risk of glucose intolerance and diabetes, and fluid retention [1].
What did IGF-I do in the CJC-1295 trials?
After one dose of the DAC form, mean IGF-I rose 1.5- to 3-fold for 9 to 11 days [2]. One week after a single 60 or 90 microgram/kg dose it was 45% above baseline, with no significant difference between doses [3].
Does CJC-1295 affect liver or kidney markers?
No effect is established. Liver injury and kidney injury are not among the safety concerns FDA lists for CJC-1295; that list covers immunogenicity for certain routes, impurity and characterization problems, and serious adverse events including increased heart rate and systemic vasodilatory reaction [4].
How long does CJC-1295 stay active?
In healthy adults given the DAC form, the estimated half-life after one subcutaneous dose was 5.8 to 8.1 days, and mean IGF-I stayed above baseline for 9 to 11 days [2].
Show all 9 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. U.S. Food and Drug Administration.
  8. Reddit participants. Assistance/Information or Reviews of CJC1295 & Ipamorelin (r/Peptidesource). Accessed 2026-11-10.
  9. Reddit participants. CJC-1295 Reviews (r/Peptidesource). Accessed 2026-11-10.
Evidence overview for CJC-1295 Effect on CMP (Comprehensive Metabolic Panel): What Labs Actually Change